🇺🇸 FDA
Patent

US 12404505

Delivery of a gene-editing system with a single retroviral particle and methods of generation and use

granted A61KA61K48/0091

Quick answer

US patent 12404505 (Delivery of a gene-editing system with a single retroviral particle and methods of generation and use) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K48/0091